Rob Scott, chief medical officer and executive vice president for research and development at AtheroGenics, has resigned, the company said Thursday.

G. Alexander Fleming, chief executive officer of consulting firm Knexum, was named interim CMO, the company said.

Fleming, a former senior physician with the U.S. Food and Drug Administration, focuses on diabetes therapeutics.

AtheroGenics is pursuing development of a drug for diabetes treatment.